Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1-2 Dose-escalation and Expansion Study of ST101 in Patients With Advanced Unresectable and Metastatic Solid Tumors

Next Previous
Trial Profile

A Phase 1-2 Dose-escalation and Expansion Study of ST101 in Patients With Advanced Unresectable and Metastatic Solid Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lucicebtide (Primary) ; Temozolomide
  • Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; Colorectal cancer; Glioblastoma; Liver cancer; Lung cancer; Male breast cancer; Malignant melanoma; Oesophageal cancer; Prostate cancer; Sarcoma; Skin cancer; Solid tumours; Uveal melanoma
  • Focus Adverse reactions; Proof of concept
  • Sponsors Sapience Therapeutics

Most Recent Events

  • 02 Jun 2025 According to a Sapience Therapeutics media release, company has completed the main portion of phase 2 dose expansion study in recurrent glioblastoma.
  • 02 Jun 2025 Results presented in a Sapience Therapeutics media release
  • 02 Jun 2025 According to a Sapience Therapeutics media release, updated positive clinical and biomarker data from phase 2 clinical trial of lucicebtide, in patients with glioblastoma and the data were featured during an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30-June 3, 2025, in Chicago and online.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top